[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seborrheic-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seborrheic-dermatitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,73,96,122,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100646899","phase-3-efficacy-and-safety-of-roflumilast-foam-03-in-trial-participants-with-seborrheic-dermatitis-100646899",false,"NCT07683806","Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis","A Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis","Inclusion Criteria:\n\n1. Males and females ages 9 years and older (inclusive) at the time of consent.\n2. Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at screening as determined by the Investigator. Stable disease for the past 4 weeks.\n3. Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and\u002For face and\u002For trunk and\u002For intertriginous areas.\n4. An Investigator Global Assessment (IGA) disease severity of at least moderate ('3') at baseline.\n5. Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.\n6. Trial participants in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.\n7. Women of Childbearing Potential (WOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). WOCBP must have used highly effective contraception for at least 4 weeks prior to the first study drug administration, and agree to continue using highly effective contraception for 2 months after the last dose. If hormonal contraceptives are used, the dosage must have been stable for a minimum of 4 weeks before the first administration. Alternatively, WOCBP shall use barrier contraception from the time of signing the ICF through 2 months after the last dose. All WOCBP shall have no plan to conceive or donate oocytes throughout the study period.\n8. Trial participants are considered reliable and capable of adhering to the protocol and visit schedule according to the Investigator judgment.\n9. Participants legally competent to sign and give informed consent or (for children\u002Fadolescents) assent with consent of a parent(s) or legal guardian.\n\nExclusion Criteria:\n\n1. Trial participants with any serious medical condition or clinically significant laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.\n2. Any conditions in the treatment area judged by the investigator at screening or baseline that may interfere with efficacy assessment (e.g., confirmed cutaneous bacterial, viral or parasitic infections, psoriasis, atopic dermatitis, acne, as well as pigmentation, extensive scars, pigmentary lesions, sunburn, etc.).\n3. Trial participants with active pityriasis\u002Ftinea amiantacea.\n4. Current or history of cancer within 5 years from Screening with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix.\n5. A clinically relevant history of abuse of alcohol or other drugs within 6 months prior to screening.\n6. Known or suspected severe renal insufficiency as evidenced by calculated creatinine clearance \\\u003C30 mL\u002Fmin, or moderate to severe hepatic disorders (Child-Pugh B or C).\n7. History of severe depression, suicidal ideation or behavior, Baseline\u002FScreening C-SSRS (for adolescents and adults 12 years old and older) indicative of suicidal behavior, whether lifetime or recent\u002Frecurrent.\n8. Trial participants with PHQ-8 (≥18 years old, inclusive) score ≥10 at Screening or Baseline visits, or children aged 9 to 11 years (inclusive), following discussion with their legal representatives, the investigator assesses the presence of depressive symptoms or suicide\u002Fdepression risk.\n9. Systemic administration of antifungals, glucocorticoids, immunosuppressants, retinoids, roflumilast tablets, apremilast tablets, or systemic traditional Chinese medicine known or suspected to affect seborrheic dermatitis within 4 weeks prior to the first study drug administration.\n10. Receipt of phototherapy, sunbeds or any other light-emitting devices within 4 weeks prior to the first study drug administration, or planned excessive exposure of the treatment area to natural or artificial light.\n11. Use of topical medications or treatments within 2 weeks prior to the first study drug administration, including but not limited to topical antifungals, topical glucocorticoids, topical calcineurin inhibitors, topical phosphodiesterase 4 (PDE-4) inhibitors, sulfur-containing preparations, azelaic acid, metronidazole, medical devices, or topical traditional Chinese medicine known or suspected to affect seborrheic dermatitis.\n12. Use of medicinal shampoos or medical devices containing antifungals, glucocorticoids, zinc pyrithione, selenium sulfide, coal tar, or keratolytic agents (e.g., salicylic acid) within 2 weeks prior to the first study drug administration.\n13. Receipt of topical treatments on the scalp for indications other than seborrheic dermatitis within 2 weeks prior to the first study drug administration, if such treatments may alter scalp skin conditions (e.g., topical minoxidil for androgenetic alopecia, retinoids or tar preparations for scalp psoriasis, topical anti-allergic agents for allergic dermatitis, and certain oil-control or anti-dandruff shampoos).\n14. Use of potent cytochrome P450 (CYP) 3A4 inhibitors systemically within 2 weeks prior to the first study drug administration.\n15. Intravenous administration of antibiotics or antiviral agents within 1 week prior to the first study drug administration.\n16. Use of etanercept within 4 weeks prior to the first study drug administration, or use of any other biologics within 12 weeks or 5 half-lives (whichever is longer) prior to the first study drug administration.\n17. Participation in any clinical trial of biologics within 12 weeks or 5 half-lives (whichever is longer), any clinical trial of oral formulations within 5 half-lives, or any clinical trial of topical formulations within 2 weeks prior to the first study drug administration (excluding participants who only signed the ICF and did not receive any study drug or device).\n18. Participants who have undergone major surgery within 4 weeks prior to the first study drug administration or are scheduled to receive major surgery during the study period .\n19. Prior use of roflumilast cream or roflumilast foam.\n20. Known allergies or hypersensitivity to component(s) of the investigational product which includes roflumilast, petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.\n21. Liver function test results excursions that exceed: AST or ALT \\> 2x ULN; Total bilirubin: 1.5x ULN or \\>ULN and ≤1.5x ULN and direct bilirubin is \\>35% of total bilirubin; ALP ≥ 2x ULN.\n22. History of human immunodeficiency virus (HIV) infection or suspected HIV infection, or positive HIV antibody at screening; positive hepatitis B surface antigen (HBsAg), or negative HBsAg with positive hepatitis B core antibody and HBV-DNA level above the upper limit of normal reference range; positive hepatitis C virus (HCV) antibody with HCV-RNA level above the upper limit of normal reference range; positive treponemal-specific antibody for syphilis (Participants with negative non-specific syphilis antibody and clinically diagnosed as inactive infection may be enrolled). Participants with indeterminate screening results are not recommended for enrollment.\n23. Trial participants\u002Fcaregivers unable to apply product to the scalp due to physical limitations if the trial participants has current or history of seborrheic dermatitis involving the scalp.\n24. Females who are pregnant, or are breast-feeding.\n25. Trial participants who are family members of the clinical study site, or clinical study staff, or sponsor, or family members residing in the same household of enrolled trial participants.\n26. Trial participants, parent(s)\u002Flegal guardian(s) of children\u002Fadolescent trial participants who are unable to communicate, read, or understand the study.\n27. Any condition that in the Investigator's assessment would preclude the trial participants from participating in the study","ALL","9 Years",{"count":19,"type":20},309,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.",[26],"Seborrheic Dermatitis",[28,29],"Roflumilast foam","seborrheic dermatitis","NOT_YET_RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":20},"2026-08-24",{"date":38,"type":20},"2027-08-03",{"name":40,"class":41},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","INDUSTRY",52,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100649468","early-phase-1-the-effectiveness-of-itraconazole-pulse-therapy-vs-topical-2-ketoconazole-in-the-treatment-of-moderate-to-severe-seborrheic-dermatitis-of-scalp-100649468","NCT07734441","The Effectiveness of Itraconazole Pulse Therapy vs Topical 2% Ketoconazole in the Treatment of Moderate to Severe Seborrheic Dermatitis of Scalp.","The Effectiveness of Itraconazole Pulse Therapy vs Topical 2% Ketoconazole in the Treatment of Moderate to Severe Seborrheic Dermatitis of Scalp. A Randomized Control Trial","Inclusion Criteria:\n\n* Patients who are interested in taking part in research are between the ages of 14-17 with people who have scalp SD ranging from moderate to severe.\n\nExclusion Criteria:\n\n* Patients with heart disease. Pregnant women or lactating women liver disease patients as itraconazole can be hepatotoxic uncontrolled hypertension patient taking multiple drugs like oral antidiabetics, lipid lowering drugs, sedatives patient has history to hypersensitvity to either of drugs.","18 Years","65 Years",{"count":53,"type":20},80,[55],"EARLY_PHASE1","This study is a randomized controlled trial comparing the effectiveness of oral itraconazole pulse therapy versus topical 2% ketoconazole shampoo in treating moderate to severe scalp seborrheic dermatitis (SD). SD is a chronic inflammatory skin condition associated with Malassezia yeast, characterized by scaling, itching, and redness, significantly affecting quality of life.\n\nA total of 80 participants aged (14-70 years) with moderate to severe scalp SD will be enrolled and divided into two groups. Group A will receive oral itraconazole (pulse regimen over 6 months), while Group B will use ketoconazole shampoo (initial daily use followed by twice weekly application). Outcomes will be assessed using the Scalp Seborrheic Dermatitis (SSD) score, Clinical Global Impression (CGI) scale, and Patient Global Impression (PGI) scale.\n\nThe study aims to compare:\n\nTreatment effectiveness Frequency of disease relapses Patient satisfaction Side-effect profiles Data will be analyzed using statistical tests (t-tests and chi-square), with significance set at p \\\u003C 0.05.\n\nThe hypothesis is that oral itraconazole pulse therapy is more effective than topical ketoconazole in controlling symptoms and preventing relapses in scalp SD.",[26],[29,59,60],"scalp seborrheic dermatitis","moderate to severe disease","RECRUITING","2026-07-24",{"date":64,"type":34},"2026-07-29",{"date":66,"type":34},"2026-01-07",{"date":68,"type":20},"2026-09-07",{"name":70,"class":71},"Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":72},"100624007","phase-1-zyg24002-lotion-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-in-adult-patients-with-mild-to-moderate-seborrheic-dermatitis-100624007","NCT07404033","ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅰb Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Different Concentrations of ZYG24002 Lotion in Adult Patients With Mild to Moderate Seborrheic Dermatitis","Inclusion Criteria:\n\n1. Aged 18 (inclusive) to 65 (inclusive) years, of either sex. Male subjects must have no childbearing potential or agree to adopt contraceptive measures until 3 months after the end of the study; female subjects of childbearing potential must be non-pregnant and non-lactating, and adopt reliable contraceptive measures during the study period and within 3 months after the last dose.\n2. Diagnosed with seborrheic dermatitis by a dermatologist (diagnostic criteria refer to the Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Seborrheic Dermatitis (2024 Edition) and the 2015 Asian Consensus on Seborrheic Dermatitis), with a disease duration of ≥ 3 months; baseline Investigator's Global Assessment for Seborrheic Dermatitis (IGA-SD) score (0-4 point scale) of 2 (mild) or 3 (moderate); at baseline, the overall scores for erythema and scaling are at least mild severity (score 1) respectively. The involved body surface area (BSA%) is ≤ 10%, and skin lesions are distributed in at least two anatomical sites such as the scalp, face, and trunk.\n3. No obvious signs of infection at the test site (e.g., pustules, crusts caused by bacterial infection). The subject is in good general skin condition at enrollment, with no other active skin lesions that may interfere with the clinical assessment.\n4. Has not participated in any other clinical trials or used any investigational drugs within the past 3 months.\n5. Study participants provide informed consent to participate in this study, sign the informed consent form (ICF), are able to understand the study requirements, and are willing to complete all scheduled visits and examinations in accordance with the investigator's instructions.\n\nExclusion Criteria:\n\n1. Severe active seborrheic dermatitis: IGA-SD score of 4 points or extensive skin lesions (BSA \\> 10%), accompanied by obvious exudation and infection, requiring systemic therapy. Participants whose disease activity is deemed unsuitable for study enrollment by the investigator (including but not limited to situations where 4 weeks of placebo-only treatment may lead to unacceptable disease progression).\n2. Comorbidities of other skin diseases that may interfere with study assessments, such as psoriasis, severe acne, rosacea, atopic dermatitis, etc., which would confound the observation of seborrheic dermatitis lesions.\n3. Administration of systemic glucocorticoids, systemic retinoids, immunosuppressants, oral\u002Fintravenous antifungals, phototherapy, PDE-4 inhibitors, or JAK inhibitors within 4 weeks; topical glucocorticoids, calcineurin inhibitors, PDE-4 inhibitors, antifungals, retinoids, keratolytics, selenium\u002Ftar-containing preparations on the study area within 2 weeks; any biologic agents within 6 months; or potent CYP3A4 inhibitors\u002Finducers within 4 weeks.\n4. Receipt of physical or chemical cosmetic treatments on the head and face within the past month (e.g., intense pulsed light, glycolic acid peels), resulting in temporary skin barrier dysfunction that has not yet recovered to normal.\n5. A history of known severe hypersensitivity or severe adverse reactions to ZYG24002 or its excipients.\n6. Comorbidities of other skin diseases that may increase the systemic absorption of ZYG24002, such as Netherton syndrome or erythroderma.\n7. Current use of immunosuppressants or diagnosis of immune deficiency.\n8. A history of malignancy within 5 years prior to screening or at screening.\n9. Poorly controlled chronic diseases, including but not limited to endocrine disorders (e.g., diabetes mellitus with significantly elevated fasting blood glucose and obvious clinical symptoms, hyperthyroidism); a history of severe cardiovascular and cerebrovascular diseases (e.g., myocardial infarction, stroke); active peptic ulcers or chronic inflammatory bowel disease, etc.\n10. Abnormal liver function: ALT or AST \\> 2 × upper limit of normal (ULN), or total bilirubin \\> 1.5 × ULN at screening; abnormal renal function: serum creatinine \\> 1.5 × ULN; or other clinically significant abnormal laboratory findings that are deemed unsuitable for enrollment by the investigator.\n11. Human immunodeficiency virus (HIV) infection; active hepatitis C virus (HCV) infection (anti-HCV positive); active hepatitis B virus (HBV) infection (HBV-DNA \\> 2000 IU\u002FmL or 10⁴ CPs\u002FmL); or positive treponema pallidum antibody with evidence of active infection.\n12. Diagnosis of psychiatric or neurological disorders that may affect compliance or increase study-related risks.\n13. Pregnancy, lactation, or planned pregnancy; female subjects of childbearing potential who have not initiated reliable contraceptive measures at least 30 days prior to the first dose and who cannot commit to maintaining such measures for 3 months after the last dose.\n14. Diagnosis of alcohol or addictive substance dependence within the past 12 months, or other conditions that the investigator believes may compromise study compliance.\n15. Any other conditions that the investigator deems may interfere with study results or pose an unacceptable safety risk to the participant.",{"count":81,"type":20},48,[83],"PHASE1","This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ib clinical trial conducted in adult patients with mild to moderate seborrheic dermatitis (IGA-SD score of 2-3 points). The study aims to evaluate the safety, tolerability, and steady-state pharmacokinetic (PK) profiles of three concentrations (0.5%, 0.75%, and 1.0%) of ZYG24002 Lotion following continuous topical application once daily (QD) or twice daily (BID) for 28 days, and to conduct a preliminary exploration of the drug's efficacy.",[26],[29],"2026-06-16",{"date":89,"type":34},"2026-06-17",{"date":91,"type":34},"2026-04-24",{"date":93,"type":20},"2026-12-31",{"name":95,"class":41},"Sinomune Pharmaceutical Co., Ltd",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":50,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":72},"100642448","a-study-on-scalp-health-and-integrated-scalp-management-protocols-for-hair-transplant-patients-100642448","NCT07641686","A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients","Inclusion Criteria:\n\n1. Healthy Chinese male subjects aged between 18 and 55 years old;\n2. Diagnosed with androgenetic alopecia, with alopecia grade from Grade II to Grade VI per Hamilton-Norwood classification;\n3. Scheduled to receive hair transplantation; scalp condition is confirmed suitable for trial participation by dermatologist assessment after hair graft surgery;\n4. With or without mild-to-moderate scalp seborrheic dermatitis (SD score ranging from 0 to 9);\n5. No anti-dandruff shampoo used within the latest 14 days prior to enrollment;\n6. No hair dyeing, perming or hair styling cosmetic treatments in the past 30 days;\n7. Able to comply with all scheduled study visits;\n8. Possess normal communication and comprehension capacity;\n9. Agree to regular follow-up visits and complete related questionnaires on time;\n10. Fully understand trial procedures, volunteer to join the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Suffering from severe scalp seborrheic dermatitis;\n2. Received oral or topical antifungal drugs, glucocorticoids or other therapeutic medicines for seborrheic dermatitis within the preceding 30 days;\n3. Complicated with other scalp diseases (such as psoriasis), or with obvious infection or unhealed wounds on the target treatment area;\n4. Known hypersensitivity to ingredients including selenium disulfide, salicylic acid and related components;\n5. History of autoimmune diseases or severe organic diseases involving heart, brain, lung, liver, kidney and other vital organs;\n6. Past medical history of psychiatric or psychological disorders;\n7. Refuse to sign the written informed consent form;\n8. Currently enrolled in another interventional clinical trial;\n9. Diagnosed with alopecia areata, pseudopelade, cicatricial alopecia or other scalp and hair disorders;\n10. Have taken part in any other clinical trial within the prior 3 months;\n11. Judged as inappropriate for trial participation based on investigator's clinical assessment.",true,"MALE","55 Years",{"count":106,"type":20},120,[108],"NA","A total of 120 Chinese male subjects aged 18-50 years who have undergone hair transplantation are planned to be enrolled in this study. Among them, 90 participants with mild-to-moderate scalp seborrheic dermatitis (hereinafter abbreviated as SD) will be stratified and randomly allocated into two groups based on a randomization table with stratification factors including SD severity grading, alopecia classification and age. Subjects in the test product group (hereinafter referred to as the holistic group) will use the test shampoo plus basic shampoo, while those in the basic control group will receive only basic shampoo. The remaining 30 non-SD subjects will constitute the non-SD control group and use basic shampoo alone.\n\n1. Primary Objective To compare pre- and post-treatment changes in clinical, physiological, biological and microecological parameters related to SD manifestations, scalp health and skin barrier repair (including transepidermal water loss, scalp hydration, scalp sebum content, etc.) between the holistic group receiving the investigational shampoo regimen and the basic control group via non-invasive instrumental measurement, clinical assessment, clinical photography and subject self-evaluation. The safety and efficacy of the test product in improving scalp condition and skin barrier function will be evaluated, and its potential underlying mechanisms will be explored.\n2. Secondary Objective To investigate the impacts of the test product versus the control shampoo on hair transplant-associated complications (e.g., folliculitis), wound healing, follicular shedding phase, graft survival rate and hair growth parameters among SD patients.\n3. Exploratory Objective To collect baseline clinical, physiological, biological and scalp microecological data from non-SD recipients after hair transplantation for reference purposes.",[111,26,112],"Hair Transplantation","Scalp Care","2026-06-08",{"date":115,"type":34},"2026-06-11",{"date":117,"type":34},"2025-02-21",{"date":119,"type":20},"2027-12-30",{"name":121,"class":41},"ChinaNorm",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":102,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100635218","sebum-metabolomics-and-lipidomics-for-clinical-applications-100635218","NCT07549828","Sebum Metabolomics and Lipidomics for Clinical Applications","Development of a Sample Collection Protocol and a Metabolomics\u002FLipidomics Analytical Strategy for Investigating Sebum and Its Clinical Applications","A. Healthy Participants\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.\n* No diagnosed skin diseases or chronic systemic diseases.\n* No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Presence of acute or chronic skin diseases, or chronic systemic diseases.\n* Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nB. Participants with Skin Diseases or Specific Skin Conditions\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Diagnosed by a physician or clinically assessed as having one of the following:\n\n  * Acne\n  * Atopic dermatitis\n  * Seborrheic dermatitis\n  * Psoriasis\n  * Other common skin diseases\n  * Specific skin conditions (e.g., postmenopausal or aging-related skin changes)\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nC. Participants Receiving Dermatological Treatments or Using Skincare Products\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:\n\n  * Physician-prescribed topical dermatological medications\n  * Physician-prescribed systemic therapies (oral or injectable)\n  * Routine use of general skincare products\n  * Physician-directed non-invasive dermatological treatments\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nD. Healthy Participants Undergoing Short-term Antibiotic Intervention\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity.\n* Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).\n* Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.","20 Years",{"count":131,"type":20},200,[108],"This study aims to develop a standardized workflow for sebum sampling and metabolomics\u002Flipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.",[135,136,26,137,138],"Acne","Atopic Dermatitis","Psoriasis","Healthy Subjects (HS)",[140,141,142,143,144,145],"Sebum","Lipidomics","Metabolomics","Skin microbiome","Sebutape","LC-MS\u002FMS","2026-04-17",{"date":91,"type":34},{"date":149,"type":20},"2026-04-01",{"date":151,"type":20},"2029-03-31",{"name":153,"class":71},"National Taiwan University Hospital",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":102,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":72},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":161,"type":20},150,[108],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[135,165,166,26],"Melasma","Rosacea",[168,169],"Artificial Intelligent","Skin","2024-08-26",{"date":172,"type":34},"2024-08-27",{"date":174,"type":34},"2023-06-06",{"date":176,"type":20},"2025-02-28",{"name":178,"class":41},"Integrative Skin Science and Research"]